RxDoctor Payments Data

Steven Ogden, MD

Adult Reconstructive Orthopaedic Surgery · Fort Worth, TXNPI 1114123080

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,875 of the $35,879 with a category attached, or 74.9%. Zimmer Biomet accounts for 83.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $20,133 and has fallen 83.0% since, to $3,419 in 2025.

$35,879in general payments, 2019–2025

Across 113 payments — averaging $317.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$30K
  • Stryker$5K
  • Alafair Biosciences, Inc.$123
  • GSK$106
  • Johnson & Johnson$101
  • Smith+Nephew$69
  • plus $202 from 8 others

What the payments were for

  • Consulting fees$26,87575%
  • Travel & lodging$4,34812%
  • Food & beverage$4,65613%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,879 in reported general payments places this provider in the 75th percentile of 86 adult reconstructive orthopaedic surgery providers in Texas.

See all adult reconstructive orthopaedic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$323,564
Medicare patients
463
Services billed
2,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban21$13,401
Celecoxib207$6,616
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen372$4,675
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$582
Doxycycline Hyclate33$395
Tramadol Hcl47$263
Cyclobenzaprine Hcl37$244
Gabapentin22$232
Pregabalin13$201
Methylprednisolone24$188
Ondansetron OdtOndansetron18$179
Meloxicam50$149
Amoxicillin135$149
Tizanidine Hcl13$141
Cephalexin27$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$101$13,40121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 86 adult reconstructive orthopaedic surgery providers in Texas.

Other adult reconstructive orthopaedic surgery in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →